Webinars

MGFA webinars are designed to educate, empower, and support the Myasthenia Gravis community. Each session is developed in collaboration with experienced clinicians, researchers, and individuals living with MG, offering clear, trusted information on disease management, overall wellbeing, and the latest advances in research and treatment.

Whether you’re looking for up-to-date insights on emerging MG therapies, research developments, clinical trials, or seeking practical guidance on health and wellness as a patient or caregiver, our webinars provide evidence-based information and real-world perspectives from trusted experts across the MG community.

Learn About IMAAVY® (nipocalimab-aahu)

Tuesday, May 19, 2026 at 4:30 PM Eastern / 1:30 PM Pacific

Speaker:
Deena Rodney, APRN

This program is for patients, caregivers, and the community to learn about generalized myasthenia gravis (gMG) and IMAAVY® clinical data, the treatment journey, and resources and support. 

IMAAVY™ is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Selected Important Safety Information

IMAAVY® is not for everyone; only your healthcare provider can decide if it’s right for you. Do not use if you are allergic to IMAAVY®. Reactions have included angioedema and anaphylaxis. IMAAVY® is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY® should not receive live vaccines. Please read the Important Safety Information and the Medication Guide for IMAAVY® to learn more about these and other risks associated with IMAAVY®. Discuss any questions you have with your healthcare provider.

Please see the full Prescribing Information and Medication Guide for IMAAVY®.

Sponsored by Johnson & Johnson